- Home
- MTR vs CVKD Comparison
MTR vs CVKD Comparison
Compare MTR & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$5.30
Company Overview
Basic Information| Metric | MTR | CVKD |
|---|---|---|
| Founded | 1979 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7M | 9.9M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | MTR | CVKD |
|---|---|---|
| Price | $4.87 | $5.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 9.2K | ★ 48.7K |
| Earning Date | 03-31-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.81% | N/A |
| EPS Growth | N/A | ★ 23.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.03 | $4.21 |
| 52 Week High | $10.42 | $17.50 |
Technical Indicators
Market Signals| Indicator | MTR | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 48.52 | 47.69 |
| Support Level | $4.55 | $5.13 |
| Resistance Level | $4.89 | $8.87 |
| Average True Range (ATR) | 0.18 | 0.53 |
| MACD | 0.00 | 0.13 |
| Stochastic Oscillator | 50.66 | 61.33 |
Price Performance
Historical Comparison MTR
CVKD
About MTR Mesa Royalty Trust
Mesa Royalty Trust holds net overriding royalty interests in various oil and gas properties located in the: Hugoton field of Kansas, San Juan Basin field of New Mexico, and San Juan Basin Field of Colorado.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.